Abstract: The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso- DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

Abstract: The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.

Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.

Abstract: The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.

Abstract: A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination

Abstract: The invention provides oxogenous markers, designed and synthesized for the measurement and characterization of oxidative/nitrosative stress levels, thus enable the identification of the type of reactive ROS/NRS involved, characterization of the damaged products and their formation kinetics, and thereby the identification of pathological conditions associated with oxidative/nitrosative stress, before appearing or at the stage of development.

Abstract: Methods for obtaining modified proteins or virus with an intact native binding site and decreased antigenicity and modified proteins or virus obtainable by said methods are provided. The methods of protein or virus modification comprise masking with non-immunogenic molecules the protein or the virus surface, except for the protein or the virus binding site. Examples of modified proteins or virus that can be modified in accordance to the methods include polyclonal or monoclonal antibodies, modified replication-defective virus, hormones, and enterotoxins.

Abstract: Process for the preparation of 1'-ethoxy carbonyloxy ethyl esters of penicillins, wherein a compound of the formula ##STR1## in which A is phenyl, phenoxy or 4-hydroxyphenyl, B is hydrogen, an amino group or a protected amino group and Z is hydrogen or a cation selected from the group of alkali metal, tri (lower alkyl ) ammonium and tetra (lower alkyl) ammonium, is reacted with 1-bromoethyl ethyl carbonate in an organic solvent and when B is a protected amino group the protecting group is split off to yield a primary amino group.There are also provided novel compounds of the formula ##STR2## in which Ph is phenyl and R is CH.sub.3 -- or C.sub.2 H.sub.5 --.

Abstract: Regio- and stereospecific method for the preparation of daunomycinone and derivatives thereof utilizing the p-nitrobenzyloxy carbonyl group as a blocking group.

Abstract: Regio- and stereospecific method for the preparation of daunomycinone and derivatives thereof utilizing the p-nitrobenzyloxy carbonyl group as a blocking group.